Roche and PTC Therapeutics have partnered for the second time in a novel three-way collaboration that sees Roche obtain a worldwide licence to PTC’s spinal muscular atrophy (SMA) programme, which includes three preclinical-stage assets as well as potential back-up compounds. The programme was developed with funding from the SMA Foundation, which will be an active participant in the collaboration.